(Reuters) – Regeneron Pharmaceuticals Inc beat Wall Street estimates for first-quarter profit on Thursday, driven by strong demand for eczema treatment Dupixent.
Excluding items, the company reported a profit of $10.09 per share for the quarter, above analysts’ estimates of $9.56, according to Refinitiv data.
(This story has been corrected to remove reference to Eylea in the headline and paragraph 1)
(Reporting by Sriparna Roy and Raghav Mahobe in Bengaluru; Editing by Devika Syamnath)
